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Summary
Background.  —  Given  the  association  between  valvular  heart  disease  and  drugs  that  alter  sero-
tonin metabolism,  concerns  have  been  raised  about  the  possibility  of  an  association  between
selective  serotonin  reuptake  inhibitor  (SSRI)  use  and  drug-induced  valvular  disease.  In  France,
SSRI use  has  been  suggested  to  be  an  important  confounding  factor  in  the  development  of  heart
valve lesions  in  patients  exposed  to  benﬂuorex  in  the  context  of  the  ‘Médiator  scandal’.
Aims. —  To  address  the  relationship  between  SSRI  use  and  valve  regurgitation  and  morphology
in a  large  cohort  of  patients  exposed  to  benﬂuorex.
Methods.  —  Overall,  832  consecutive  patients  exposed  to  benﬂuorex  prospectively  referred  to
10 centres  underwent  complete  echocardiography  examinations  according  to  a  standardized
protocol. Echocardiograms  were  independently  and  blindly  read  off-line  by  two  experts.
Results.  —  Ninety  patients  had  been  exposed  to  SSRIs  for  3  months  or  more.  The  proportions  of
patients with  no  or  trivial,  mild,  moderate  or  severe  mitral  regurgitation  (MR)  or  aortic  regurgi-
tation (AR)  were  not  different  between  SSRI  patients  and  non-SSRI  patients  (P  =  0.63  and  0.58,
respectively).  The  frequencies  of  AR  ≥  mild  (20  [22.2%]  vs  145  [19.5%];  P  =  0.55)  and  MR  ≥  mild
(14 [15.6%]  vs  118  [15.9%];  P  =  0.93)  were  similar  in  SSRI  patients  and  non-SSRI  patients.  The
frequencies  of  aortic  and  mitral  valve  abnormalities  suggestive  of  drug-induced  toxicity  were
also similar  in  the  two  patient  groups.  Multivariable  logistic  regression  analysis  conﬁrmed  the
absence of  any  identiﬁable  relationship  between  AR  or  MR  and  morphological  abnormalities  and
SSRI use  in  the  present  cohort.
Conclusion.  —  Exposure  to  SSRIs  was  not  associated  with  an  increased  risk  of  heart  valve  regur-
gitation or  morphological  abnormalities  suggestive  of  drug-induced  toxicity  in  this  large  cohort
of patients  exposed  to  benﬂuorex.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Étant  donné  l’association  entre  maladies  valvulaires  cardiaques  et  médicaments
qui modiﬁent  le  métabolisme  de  la  sérotonine,  des  questions  ont  été  soulevées  sur  la  possibilité
d’une association  entre  inhibiteurs  sélectifs  de  recapture  de  la  sérotonine  (IRS)  et  maladies
valvulaires  cardiaques.  Il  a  été  suggéré  en  France  dans  le  contexte  du  « scandale  du  Médiator  »
que, l’utilisation  d’IRS  puisse  être  un  facteur  confondant  important  dans  le  développement  des
lésions valvulaires  de  patients  exposés  au  Médiator.
Objectif.  —  Le  but  de  cette  étude  était  d’évaluer  la  relation  entre  utilisation  d’IRS  et  les  fuites
et la  morphologie  valvulaire  dans  une  large  cohorte  de  patients  exposés  au  benﬂuorex.
Méthodes.  — Huit  cent  trente-deux  patients  consécutifs  exposés  au  benﬂuorex  référés  prospec-
tivement  à  dix  centres  ont  bénéﬁcié  d’examens  échocardiographiques  complets  selon  un
protocole standardisé.  Les  échocardiographies  étaient  lues  indépendamment  et  de  fac¸on  aveu-
gle en  déporté  par  deux  experts.
Résultats.  —  La  proportion  de  patients  avec  des  fuites  mitrales  ou  aortiques  —  absente  ou
triviale, moyenne,  modérée  ou  sévère  —  n’était  pas  différente  entre  les  patients  exposés
aux IRS  et  les  autres  (p  =  0,63  et  0,58,  respectivement).  Les  proportions  de  fuites  aortiques
supérieures  ou  égales  à  moyenne  (20  [22,2  %]  vs  145  [19,5  %]  ;  p  =  0,72)  et  mitrales  supérieures  ou
égales à  moyenne  (14  [15,6  %]  vs  118  [15,9  %]  ;  p  =  0,93)  étaient  comparables  entre  les  patients
traités ou  non  par  IRS.  Les  proportions  d’anomalies  aortiques  et  mitrales  suggestives  d’atteinte
médicamenteuse  étaient  également  similaires  dans  les  deux  groupes  de  patients.  Une  ana-
lyse multivariée  de  régression  logistique  a  conﬁrmé  l’absence  de  relation  identiﬁable  entre
fuites aortique  et  mitrale,  anomalies  morphologiques  valvulaires  et  utilisation  d’IRS  dans  cette
cohorte.
Conclusions.  —  L’exposition  aux  IRS  n’est  pas  associée  à  une  majoration  du  risque  de  fuites  et
d’anomalies  morphologiques  suggestives  de  toxicité  médicamenteuse  dans  cette  large  cohorte
de patients  exposés  au  benﬂuorex.
© 2013  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Background
Exposure  to  amphetamine-based  appetite  suppressant
drugs,  such  as  fenﬂuramine  and  dexfenﬂuramine,  has  been
associated  with  an  increased  risk  of  heart  valve  regur-
gitation  [1].  The  toxic  effect  of  fenﬂuramine  on  heart
valves  is  thought  to  be  related  to  local  increased  sero-
tonin  concentrations  that  promote  valvular  ﬁbrosis  via
5-hydroxytryptamine  (HT)2B receptors  [2,3].  Recently,  ben-
ﬂuorex  —  widely  prescribed  in  Europe,  Asia  and  South
America  for  type  II  diabetes  but  also  off-licence  as  a
slimming  aid  —  has  been  involved  in  the  development  of
restrictive  valvular  diseases  owing  to  its  fenﬂuramine-like
properties  [4—12].  Results  from  a  randomized  control  study
showed  that  after  1  year  of  exposure,  there  is  a  3-fold
increase  in  the  incidence  of  valvular  regurgitation  with  ben-
ﬂuorex  compared  with  pioglitazone  in  patients  with  diabetes
[13].
Selective  serotonin  reuptake  inhibitors  (SSRIs)  are  a
class  of  compounds  widely  used  as  antidepressants  in  the
treatment  of  depression,  anxiety  disorders  and  certain
personality  disorders.  Given  the  association  between  valvu-
lar  heart  disease  (VHD)  and  drugs  that  alter  serotonin
metabolism,  concerns  have  been  raised  about  the  safety
of  SSRI  therapy  [14].  Strikingly,  a  high  proportion  of  SSRI
intake  was  found  in  the  landmark  report  of  patients  with
fenﬂuramine-induced  ﬁbrotic  valvular  disease  [15]. Only  one
retrospective  study  addressed  this  issue  and  did  not  observe
a  link  between  SSRI  exposure  and  VHD  [16].  In  France,  SSRI
use  has  been  suggested  to  be  an  important  confounding  fac-
tor  in  the  development  of  heart  valve  lesions  in  patients
exposed  to  benﬂuorex  in  the  context  of  the  ‘Médiator  scan-
dal’  [14].
Following  a  French  public  health  advisory  in  late  2009,
consecutive  patients  exposed  to  benﬂuorex  referred  to  10
centres  were  included  in  a  prospective  echocardiography-
based  study  designed  to  assess  the  proportions  of  valvular
lesions  associated  with  benﬂuorex  use.  To  date,  there  are  no
data  regarding  a  potential  additional  role  for  SSRIs  in  drug-
induced  VHD  in  patients  exposed  to  benﬂuorex.  Indeed,  it
has  been  suggested  that  SSRIs  might  potentiate  the  toxic-
ity  of  benﬂuorex  on  cardiac  valves.  Given  the  systematic
prospective  data  collection,  including  SSRI  use,  and  the  blind
core  echocardiography,  this  study  provided  an  opportunity
to  investigate  the  possibility  of  an  association  between  SSRI
exposure  and  heart  valve  lesions  in  these  patients  exposed
to  benﬂuorex.
Methods
Patients
Marketing  authorization  for  benﬂuorex  was  suspended  in
France  in  November  2009  and  the  French  drug  regulatory
agency  (Agence  franc¸aise de  sécurité  sanitaire  des  pro-
duits  de  santé  [Afssaps])  issued  a  public  health  advisory
inviting  all  patients  with  previous  exposure  to  benﬂuo-
rex  to  contact  their  primary  care  physician.  Primary  care
physicians  further  referred  patients  to  a  cardiologist  for
echocardiography.  On  26  November  2009,  the  cardiology
departments  of  all  French  university  hospitals,  leading
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rivate  clinics  and  general  hospitals  were  contacted  by  e-
ail  on  behalf  of  the  French  Society  of  Cardiology  and
ere  invited  to  participate  in  this  multicentre  prospec-
ive  echocardiography  study.  Investigators  were  asked  to
rospectively  include  all  consecutive  patients  previously
xposed  to  benﬂuorex,  referred  by  their  primary  care  physi-
ians  for  echocardiography.  Ten  centres  participated  in  this
tudy  (Centre  Hospitalier  Universitaire  d’Amiens,  Centre
ospitalier  de  Beauvais,  Centre  Hospitalier  Universitaire  de
ordeaux,  Centre  Hospitalier  Universitaire  de  Brest,  Centre
ospitalier  de  Compiègne,  Centre  Hospitalier  Universitaire
e  Lille,  Groupe  Hospitalier  de  l’Institut  Catholique  de  Lille,
entre  Hospitalier  Universitaire  de  Nantes,  AP—HP  Hôpital
aint-Antoine  Paris  and  Centre  Hospitalier  Universitaire  de
ennes).  This  observational  study  was  approved  by  the  non-
nterventional  research  ethics  committee  of  the  University
f  Picardie,  Amiens,  France.  Oral  consent  was  obtained  from
ach  patient.
Consecutive  benﬂuorex-treated  patients  with  no  history
f  VHD  referred  by  primary  care  physicians  for  echocardi-
graphy  to  the  participating  centres  were  enrolled  in  the
resent  study  when  they  had  a  history  of  3  months  or  over
f  exposure  to  benﬂuorex.  All  patients  exposed  to  ben-
uorex  and  referred  for  a  second  expert  evaluation  after
nitial  echocardiography  were  not  included  in  the  present
tudy.  Patients  exposed  to  drugs  that  could  induce  VHDs
rye  ergot  alkaloids,  fenﬂuramine/phentermine,  dexfen-
uramine,  pergolide)  and  patients  with  a  cardiac  valve
rosthesis  were  excluded  from  the  present  study.
Demographic  data,  cardiovascular  risk  factors,  pres-
nce  of  symptoms  and  echocardiography  variables  were
ecorded.  Total  duration  of  treatment  by  benﬂuorex  was
ystematically  recorded.  Primary  care  physicians  were  con-
acted  by  phone  at  the  time  of  the  echocardiography  when
here  was  any  doubt  concerning  exposure  to  SSRIs  or  other
edications.  Patients  were  classiﬁed  in  the  SSRI  group  when
hey  had  been  exposed  to  SSRIs  for  3  months  or  over.  Three
atients  in  whom  there  was  ﬁnally  a  doubt  about  exposure
o  SSRI  were  excluded  from  the  present  study.
chocardiography
omplete  echocardiography  examinations  on  commercially
vailable  ultrasound  devices  were  performed  in  each  centre
y  experienced  operators  according  to  a  standardized  pro-
ocol  with  multiple  two-dimensional  views  and  the  use  of
arious  Doppler  modes.  Views  of  the  mitral,  aortic,  tricus-
id  and  pulmonary  valves  were  obtained  whenever  possible.
o  this  effect,  magniﬁed  video  loops  were  recorded  in
arasternal  long-axis  views  for  the  aortic  and  mitral  valves,
arasternal  short-axis  view  for  the  pulmonary,  tricuspid  and
ortic  valves,  apical  views  for  the  tricuspid,  mitral  and  aortic
alves,  and  subcostal  view  for  all  valves,  whenever  possi-
le.  All  recordings  were  obtained  with  and  without  Doppler
olour  ﬂow  mapping.  All  echocardiography  examinations
ere  stored  in  digital  DICOM  format  on  digital  versatile  disks
or  subsequent  off-line  analysis.
All  echocardiograms  were  independently  read  by  two
ardiologists  who  were  experts  in  echocardiography  and
HD  and  were  blinded  to  all  aspects  of  the  patient’s  his-
ory,  including  SSRI  use,  to  assess  heart  valve  morphology
nd  regurgitation.  In  the  event  of  disagreement  between
352  S.  Maréchaux  et  al.
Figure 1. Apical long-axis two-dimensional views magniﬁed on the mitral valve in systole (A) and diastole (B), and colour Doppler ﬂow
mapping in systole (C), showing leaﬂet thickening associated with thickening and shortening of the chordae tendineae and retraction of one
o ick ap
o tatio
t
a
s
t
m
[
i
E
t
(
t
r
o
t
t
F
ﬂ
s
ar both leaﬂets with reduced valve mobility, with a typical drumst
f drug-induced valvular heart disease and moderate mitral regurgi
he  two  readers,  a  third  independent  expert  performed
 ﬁnal  blinded  reading  and  provided  a  ﬁnal  grading.  The
everity  of  valve  regurgitation  was  classiﬁed  as  absence  or
race,  mild,  moderate  or  severe,  according  to  the  recom-
endations  of  the  European  Society  of  Echocardiography
17,18].  The  moderate  regurgitation  group  was  subdivided
nto  ‘mild-to-moderate’  and  ‘moderate-to-severe’  [17,18].
chocardiography  features  of  drug-induced  VHD  were  sys-
ematically  investigated  [19,20].  For  the  mitral  valve
i
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igure 2. Parasternal long-axis two-dimensional views magniﬁed on t
ow mapping in parasternal long-axis (C) and short-axis (D) views, show
mall central triangular valve hiatus during diastole and presence of a su
bnormalities being suggestive of drug-induced valvular heart disease. Apearance, in a patient with mitral valve abnormalities suggestive
n. MR: mitral regurgitation; MV: mitral valve.
Fig.  1),  these  features  were  leaﬂet  thickening,  retraction
owards  the  ventricular  apex  during  systole  (leaﬂet  tenting),
educed  valve  mobility  and/or  thickening  and  shortening
f  the  chordae  tendineae.  For  the  aortic  valve  (Fig.  2),
hese  features  were  systolic  subtle  dome-like  appearance  of
he  leaﬂets,  valvular  thickening,  reduced  mobility  and/or
ncomplete  diastolic  coaptation  resulting  in  a  small  cen-
ral  triangular  valve  hiatus  during  diastole  in  the  short-axis
iew,  with  central  aortic  regurgitation  (AR).  Based  on  this
he aortic valve in systole (A) and diastole (B), and colour Doppler
ing central aortic regurgitation, leaﬂet thickening, presence of a
btle dome-like appearance of the aortic valve during systole, these
R: aortic regurgitation; AV: aortic valve.
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Table  1  Demographic  and  clinical  characteristics  of  the  study  population.
SSRI  No  SSRI  P
(n  =  90)  (n  =  742)
Age  (years)  54  ±  10  59  ±  12  <  0.0001
Women  68  (76)  418  (56)  <  0.0001
Body  mass  index  (kg/m2)  32  ±  7  31  ±  6  0.178
Diabetes  44  (49)  368  (50)  0.91
Hyperlipidaemia  67  (74) 418  (56)  0.001
Hypertension  46  (51) 408  (55) 0.486
Past  or  current  smoker 22  (24) 133  (18) 0.151
History  of  CAD 8  (9) 71  (10) 0.784
History  of  heart  failure  2  (2)  26  (4)  0.759
Heart  murmur  4  (4)  51  (7)  0.309
NYHA  III—IV  10  (12)  59  (8)  0.274
Data are mean ± standard deviation or number (%). CAD: coronary artery disease; NYHA: New York Heart Association; SSRI: selective
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blind  qualitative  analysis,  echocardiography  valvular  fea-
tures  were  classiﬁed  as:  highly  suggestive  of  drug-induced
VHD;  inconclusive;  and  not  suggestive  of  drug-induced  VHD.
Left  ventricular  end-diastolic  and  end-systolic  diameters
were  obtained  from  parasternal  long-axis  views.  Left  ven-
tricular  ejection  fraction  was  calculated  using  Simpson’s
biplane  method.  The  quality  of  the  echocardiograms  was
graded  semiquantitatively  into  four  grades  (1:  excellent;  2:
good;  3:  average;  and  4:  poor).
Statistical analysis
Continuous  variables  are  expressed  as  mean  ±  standard  devi-
ation  or  median  [25th—75th  percentiles]  as  appropriate.
Categorical  variables  are  expressed  as  absolute  numbers  and
percentages.  Comparisons  between  continuous  variables
were  performed  with  Student’s  t-test  or  the  Mann-Whitney
U  test,  as  appropriate.  Comparisons  between  categorical
variables  were  performed  using  Chi-square  or  Fisher’s  exact
test,  as  appropriate.  The  association  between  SSRI  use  and
left  heart  valve  regurgitation  ≥  mild  or  moderate  and  pres-
ence  of  heart  valve  abnormalities  suggestive  of  drug-induced
VHD  was  tested  using  complete  instead  of  stepwise  multi-
ple  logistic  regression  analysis.  Age,  sex,  body  mass  index,
smoking,  hyperlipidaemia,  hypertension,  diabetes,  coronary
artery  disease,  New  York  Heart  Association  (NYHA)  func-
tional  class  III—IV,  presence  of  cardiac  murmur  and  duration
of  benﬂuorex  therapy  were  a  priori  included  in  the  multi-
variable  model.  Agreement  between  readers  for  the  severity
of  aortic  or  mitral  regurgitation  (MR)  (none  or  trace,  mild,
moderate,  severe)  and  for  aortic  or  mitral  valve  morphol-
ogy  (highly  suggestive  of  drug-induced  VHD;  inconclusive;
not  suggestive  of  drug-induced  VHD)  was  assessed  using  the
kappa  value.  A  two-tailed  P  value  <  0.05  was  deemed  signiﬁ-
cant.  All  analyses  were  performed  using  PASW  Statistics  18.0
(IBM,  Inc.,  Bois-Colombes,  France).Results
Of  the  832  patients  included  in  this  study,  90  had  taken
SSRIs,  which  were  prescribed  for  depression  in  64  patients
[
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f71%)  and  anxiety  disorders  in  26  patients  (29%).  The  char-
cteristics  of  the  study  population  according  to  SSRI  use
re  detailed  in  Table  1. Patients  who  had  taken  SSRIs  were
lder  and  had  a  higher  rate  of  hyperlipidaemia.  The  propor-
ions  of  patients  in  NYHA  class  III—IV  and  the  prevalence  of
eart  murmurs  were  not  different  between  the  two  groups.
f  note,  duration  of  benﬂuorex  therapy  was  not  signiﬁ-
antly  different  between  the  two  groups  of  patients  (36
24—60],  55  ±  50  months  for  SSRI  patients  vs  36  [24—60],
0  ±  49  months  for  non-SSRI  patients;  P  =  0.203).
eft-sided heart valves
roportion  of  regurgitation
n  the  overall  cohort,  237  patients  had  left  heart  valve
egurgitation  ≥  mild.  One  hundred  and  sixty-ﬁve  (19.8%)
atients  had  ≥  mild  AR  and  132  (15.9%)  had  ≥  mild  MR.
ombined  MR  and  AR  ≥  mild  was  observed  in  60  patients
7.2%).  Six  hundred  and  sixty-seven  patients  (80.2%)  had
o  or  trivial  AR,  119  (14.3%)  patients  had  mild  AR  and  46
atients  had  moderate  AR  (5.5%;  44  mild-to-moderate  and
wo  moderate-to-severe).  Seven  hundred  (84.1%)  patients
ad  no  or  trivial  MR.  Mild  MR  was  observed  in  120  patients
14.4%)  and  moderate  MR  was  observed  in  12  patients  (1.4%;
ight  mild-to-moderate  and  four  moderate-to-severe).  No
atients  had  severe  AR  or  MR.
As  shown  in  Table  2, the  proportion  of  patients  with
o  or  trivial,  mild,  moderate  or  severe  MR  or  AR  was  not
ifferent  between  SSRI  patients  and  non-SSRI  patients.  Over-
ll,  the  frequencies  of  left  heart  valve  regurgitation  ≥  mild
28  [31.1%]  vs  209  [28.2%];  p  =  0.559)  and  ≥  moderate  (4
4.4%]  vs  51  [6.9%];  p  =  0.38)  were  similar  between  SSRI
atients  and  non-SSRI  patients.  The  frequency  of  com-
ined  AR  and  MR  ≥  mild  was  also  not  signiﬁcantly  different
etween  SSRI  patients  and  non-SSRI  patients  (6  [6.7%]  and  54
7.7%];  P  =  0.832).  The  frequencies  of  AR  ≥  mild  (20  [22.2%]
s  145  [19.5%];  P  =  0.55)  and  MR  ≥  mild  (14  [15.6%]  vs  118
15.9%];  P  =  0.93)  were  also  similar  in  SSRI  patients  and  non-
SRI  patients.  Moreover,  all  12  patients  with  MR  ≥  moderate
ere  in  the  non-SSRI  group  (1.6  vs  0%;  P  =  0.63),  whereas
our  patients  (4.4%)  had  AR  ≥  moderate  in  the  SSRI  group
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Table  2  Left  heart  valve  regurgitations  and  morphology  abnormalities  according  to  selective  serotonin  reuptake  inhibitor
(SSRI)  exposure.
SSRI  No  SSRI P
(n  =  90)  (n  =  742)
Aortic  regurgitation 0.580
None  or  trace 70  (77.8) 597  (80.5)
Mild  16  (17.8) 103  (13.9)
Moderate  4  (4.4)  42  (5.7)
Severe  0  (0)  0  (0)
Mitral  regurgitation  0.632
None  or  trace  76  (84.4)  624  (84.1)
Mild  14  (15.6)  106  (14.3)
Moderate  0  (0)  12  (1.6)
Severe  0  (0)  0  (0)
Aspect  and  motion  of  aortic  valve  0.757
Highly  suggestive  of  drug-induced  VHD  3  (3.3)  27  (3.6)
Inconclusive  6  (6.7)  39  (5.3)
Not  suggestive  of  drug-induced  VHD  81  (90)  676  (91.1)
Aspect  and  motion  of  mitral  valve  0.664
Highly  suggestive  of  drug-induced  VHD  4  (4.4)  39  (5.3)
Inconclusive  4  (4.4)  21  (2.8)
Not  suggestive  of  drug-induced  VHD  82  (91.1)  682  (91.9)
Data are number (%). SSRI: selective serotonin reuptake inhibitors; VHD: valvular heart disease.
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pompared  with  42  patients  (5.7%)  in  the  non-SSRI  group
P  =  0.809).  In  the  multivariable  logistic  regression  analysis,
xposure  to  SSRIs  remained  not  associated  with  AR  ≥  mild
P  =  0.382)  and/or  MR  ≥  mild  (P  =  0.575).
haracterization  of  valvular  abnormalities
verall,  57  patients  had  heart  valve  abnormalities  highly
uggestive  of  drug-induced  VHD:  seven  SSRI  patients  and  50
on-SSRI  patients  (P  =  0.712).  The  frequencies  of  aortic  and
itral  valve  abnormalities  highly  suggestive  of  drug-induced
HD  were  similar  in  the  two  groups  of  patients  (Table  2).  In
he  multivariable  logistic  regression  analysis,  exposure  to
SRIs  was  not  associated  with  morphological  valve  abnor-
alities  suggestive  of  drug-induced  VHD  (P  =  0.801).
ight-sided heart valves and other
chocardiographic variables
even  hundred  and  forty-four  patients  had  no  or  trivial
ricuspid  regurgitation  (TR).  Seventy-seven  patients  had
ild  TR,  10  patients  had  moderate  TR  and  one  patient
ad  moderate-to-severe  TR.  Seven  hundred  and  sixty-ﬁve
atients  had  no  or  trivial  pulmonary  regurgitation  (PR).
ixty-three  patients  had  mild  PR  and  four  had  moderate  PR.
s  for  left  heart  valves,  the  frequencies  of  PR  or  TR  ≥  mild
ere  not  signiﬁcantly  different  between  SSRI  patients  (4
4.4%]  vs  63  [8.5%];  P  =  0.178)  and  non-SSRI  patients  (8
8.9%]  vs  80  [10.8%];  P  =  0.58).  No  patient  had  tricuspid  or
ulmonary  valve  lesions  suggestive  of  drug-induced  abnor-
alities.
Left  ventricular  ejection  fraction  was  similar  between
he  two  groups  of  patients  (63  ±  5%  for  SSRIs  vs  64  ±  7%;
 =  0.36).  Left  ventricular  end-diastolic  diameter  was
f
r
i
tlightly  lower  in  SSRI  patients,  while  left  ventricular  end-
ystolic  diameter  was  not  signiﬁcantly  different  between
he  two  groups:  48  ±  5  vs  49  ±  6  mm  (P  = 0.035)  and  30  ±  5
s  31  ±  6  mm  (P  =  0.226),  respectively.
eproducibility and quality score
greement  between  readers  for  regurgitation  severity  (four
lasses:  no  or  trace,  mild,  moderate,  severe)  of  AR  and  MR
as  good,  with  kappa  values  of  0.89  and  0.90,  respectively
both  P  <  0.0001).  The  kappa  value  for  inter-reader  variabil-
ty  for  characterization  of  aortic  and  mitral  valvular  features
n  three  classes  (highly  suggestive  of  drug-induced  VHD;
nconclusive;  and  not  suggestive  of  drug-induced  VHD)  was
lso  good,  with  kappa  values  of  0.81  and  0.87,  respectively
both  P  <  0.0001).  The  mean  echocardiogram  quality  score
as  similar  in  the  two  groups  of  patients  (1.34  ±  0.55  for
SRI  patients  vs  1.33  ±  0.61  for  non-SSRI  patients;  P  =  0.856).
iscussion
he  present  data  indicate  that  exposure  to  SSRIs  was  not
ssociated  with  an  increased  risk  of  heart  valve  regurgitation
nd  heart  valve  morphological  abnormalities  suggestive  of
rug-induced  VHD  in  this  large  cohort  of  patients  exposed
o  benﬂuorex.  SSRI  exposure  is  therefore  unlikely  to  play
 role  in  the  development  of  heart  valve  lesions  in  these
atients.
The  possibility  that  drug  intake  may  be  responsible
or  onset  of  VHD  was  ﬁrst  proposed  in  the  mid-1960s  in
elation  to  ergot  alkaloids  used  for  migraine  prophylaxis,
nitially  with  methysergide  (Désernil®)  and  then  with  ergo-
amine  (Gynergène®) [1]. In  1997—98,  drug-related  VHD
ced
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PSelective  serotonin  reuptake  inhibitor  therapy  and  drug-indu
was  then  reported  with  two  appetite  suppressants,  fenﬂu-
ramine  (Pondéral®)  and  dexfenﬂuramine  (Isoméride®),  two
drugs  previously  recognized  as  being  associated  with  the
development  of  pulmonary  arterial  hypertension  [21].  These
ﬁndings  led  to  the  withdrawal  of  these  two  appetite  suppres-
sants  from  the  market.  Similar  ﬁndings  of  drug-related  VHD
with  ergot-derived  dopamine  agonists  were  then  reported  in
patients  treated  for  Parkinson’s  disease  and  hyperprolacti-
naemic  disorders  with  pergolide  (Célance®)  and  cabergoline
(Dostinex®),  respectively  [22].  More  recently,  similar  cases
of  drug-related  VHD  have  been  reported  with  prolonged
use  of  the  recreational  drug  ecstasy  (3,4-methylenedioxy-
methamphetamine;  MDMA)  [23]  and  benﬂuorex  (Médiator®)
[5,10,12,24,25],  an  amphetamine  derivative  structurally
related  to  fenﬂuramine  and  dexfenﬂuramine.  Consequently,
benﬂuorex  —  indicated  in  overweight  diabetes  patients  and
also  used  off-label  as  a  slimming  aid  —  was  withdrawn  from
the  European  market  in  2010  following  the  publication  in
several  reports  [4,6,8,9]  of  a  link  between  benﬂuorex  expo-
sure  and  the  development  of  heart  valve  regurgitation,  as
previously  observed  with  other  fenﬂuramine  derivatives.
Interestingly,  in  the  landmark  report  by  Connolly  et  al.
concerning  female  patients  with  fenﬂuramine-induced
ﬁbrotic  valvular  disease,  6/19  patients  had  been  exposed
to  SSRIs  [15].  These  data  raised  a  concern  about  the  safety
of  SSRIs,  currently  used  as  ﬁrst-line  therapy  in  affective
disorders  with  clinically  proven  efﬁcacy,  as  these  drugs
also  interfere  with  serotonin  metabolism.  Indeed,  about
one  quarter  of  patients  exposed  to  fenﬂuramine  had  been
exposed  to  SSRIs  in  some  reports  [16],  although  the  preva-
lence  of  SSRI  use  was  lower  (12%)  in  the  present  study.
As  fenﬂuramine  increases  synaptic  levels  of  5-HT,  fenﬂu-
ramine  has  been  suspected  to  induce  VHD  via  a  serotonergic
mechanism,  as  previous  studies  have  reported  that  fen-
ﬂuramine  derivatives  have  a  high  afﬁnity  for  the  5-HT2B
receptor,  and  are  full  agonists  at  the  5-HT2B site  [26].
Activation  of  the  5-HT2B serotonin  receptor  by  appetite  sup-
pressants  was  therefore  proposed  as  the  key  mechanism
leading  to  drug-induced  ﬁbrotic  valvular  disease.  Stimula-
tion  of  this  receptor  leads  to  upregulation  of  target  genes
involved  in  the  proliferation  and  stimulation  of  valvular
interstitial  cells  via  various  intracellular  pathways,  i.e.  G
protein-mediated  activation  of  protein  kinase  C,  Src  protein,
extracellular-regulated  kinases  1  and  2  and  transforming
growth  factor-beta  receptor  activation,  with  subsequent
ﬁbroblast  proliferation  and  increased  glycosaminoglycan
production  [2].  Anorexigens,  including  benﬂuorex,  inter-
fere  with  serotonin  metabolism  and  activate  the  5-HT2B
receptor  via  their  metabolite,  norfenﬂuramine.  This  type
of  5-HT2B agonist  effect  has  also  been  reported  for
ergot  alkaloids,  ergotamine  and  methysergide,  pergolide,
cabergoline,  MDMA,  ergotamine  and  methylergonovine,  a
metabolite  of  methysergide  [2].
To  the  best  of  our  knowledge,  only  one  retrospective
study,  published  by  Mast  et  al.  in  the  late  1980s,  addressed
the  relationship  between  SSRI  use  and  heart  valve  damage
[16].  In  this  cohort,  the  authors  did  not  ﬁnd  any  rela-
tionship  between  SSRI  therapy  and  valvular  regurgitation
or  morphological  abnormalities  commonly  identiﬁed  with
fenﬂuramine.  The  current  prospective  study,  using  rigor-
ous  methodology,  also  failed  to  demonstrate  any  association
between  SSRI  use  and  valve  regurgitation  and  morphological
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bnormalities.  Consistently,  SSRIs  were  not  found  to  have
ny  5-HT2B agonist  properties,  in  contrast  with  norfen-
uramine  (the  metabolite  of  fenﬂuramine  derivatives),
nd  may  even  act  as  5-HT2B antagonists  [3]. Although  5-
T1B receptors  mediate  5-HT-induced  collagen  secretion  by
uman  cardiac  myoﬁbroblasts,  this  receptor  to  SSRIs  may  not
lay  a  role  in  the  development  of  valvulopathy,  as  double-
nockout  mice  deﬁcient  in  both  5-HT  transporter  and  5-HT1B
eceptors  show  the  same  cardiac  alterations  as  5-HT  trans-
orter  knockout  mice  [27].  In  addition,  chronic  fenﬂuramine
xposure  in  rats  produced  1.7-  and  3.5-fold  increases  in
aseline  plasma  5-HT,  while  chronic  exposure  to  ﬂuoxetine
an  SSRI)  had  no  effect,  suggesting  that  serotonin  increase
y  SSRIs  may  not  play  a role  in  the  development  of  VHD  [26].
The  limited  sample  of  patients  exposed  to  SSRIs  may  limit
he  statistical  power  of  this  study.  However,  the  proportions
f  patients  with  heart  valve  regurgitation  ≥  mild  and  valve
bnormalities  suggestive  of  drug-induced  lesions  were  sim-
lar  in  patients  exposed  to  SSRIs  compared  with  those  not
xposed  to  SSRIs.  In  addition,  the  blinded  and  duplicate
chocardiography  evaluation  of  valvular  regurgitations  and
esions  strengthens  the  results  of  the  present  prospective
tudy.  In  contrast  to  the  previous  study  involving  patients
eferred  for  echocardiography  for  reasons  other  than  that
ddressed  by  the  study,  consecutive  patients  in  our  cohort
ere  speciﬁcally  and  prospectively  included  for  the  system-
tic  assessment  of  heart  valve  morphology  and  regurgitation
ollowing  a  public  health  advisory  regarding  drug-induced
HD.  Data  regarding  duration  of  SSRI  therapy  and  daily  dose
ere  not  prospectively  collected  and  were  not  available  in
he  present  study.
onclusion
n  conclusion,  data  from  the  present  study  do  not  support
 clinically  signiﬁcant  toxic  role  of  SSRIs  on  heart  valves  in
atients  exposed  to  benﬂuorex  and  may  provide  reassurance
o  physicians  and  patients  exposed  to  SSRIs.
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